204 results about "Pulmonary alveolus" patented technology

The invention relates to a nitric oxide data analysis method and system for bronchial asthma assessment. According to the method, exhaled air nitric oxide and pulmonary alveolar nitric oxide of a patient, omics data and clinical information are acquired in a standardized manner, and multi-dimensional features are constructed after data cleaning and fusion; comprise an inflammation level index, an inflammation region entropy, an inflammation synergy index, a glucocorticoid response factor, an infection-smoking synergy influence factor and a heredity-symptom distribution index. And outputting initial risk assessment based on an explainable elevator EBM model, and finally generating an asthma risk probability through a weighted integration formula to realize three-level layering: low / medium / high risk. The system dynamically associates treatment decisions, for example, the drug dosage and the monitoring frequency are improved when the risk is upgraded, and the medication scheme is optimized when the risk is degraded. According to the scheme, the limitation of traditional single marker static analysis is broken through, multiple mechanisms of dissection, immunity and pharmacology are fused, the evaluation precision and clinical applicability are remarkably improved, the acute attack rate is reduced, and accurate typing treatment is guided.

The invention provides a traditional Chinese medicine monomer composition for preventing and / or treating pulmonary fibrosis as well as a preparation and application thereof, and belongs to the technical field of biological medicines. The traditional Chinese medicine monomer composition comprises the following components: schisandrin B and platycodin D. The traditional Chinese medicine monomer composition can obviously reduce fiber cell and collagen deposition, relieve inflammatory cell infiltration, obviously reduce the lung coefficient, alveolar inflammation score and pulmonary fibrosis score, and recover the normal physiological structure of rat lung tissue. The traditional Chinese medicine monomer composition provided by the invention can reduce the expression contents of KL-6, MMP-7, SP-A and SP-D and lung tissue HYP in serum, and has the effects of relieving collagen deposition and alveolar epithelium injury, maintaining alveolar homeostasis and improving pulmonary fibrosis. Therefore, the traditional Chinese medicine composition provided by the invention is definite and reliable in curative effect and can be used for preparing medicines for preventing and / or treating pulmonary fibrosis.

The invention belongs to the technical field of biological medicine, and particularly relates to application of corynebacterium casei in preparation of medicine for preventing and treating lung injury. By constructing a radon inhalation-induced lung injury mouse model, after exposure at different radon levels, the weight of a mouse is reduced, the lung coefficient is increased, the tidal volume of the lung, the ventilation volume per minute and the maximum inspiration flow are reduced, the respiratory function is inhibited, the alveolar cavity of the mouse is abnormally expanded, the pulmonary septum is thickened and fractured, and more fibrin exudation is accompanied; the traditional Chinese medicine composition can be used for effectively inhibiting pulmonary fibrosis and lung injury due to obvious inflammatory infiltration beside bronchial tubes, extravasated blood in small blood vessels and lung tissue collagen deposition, and can be used for gavage of corynebacterium casei to effectively inhibit the above phenomena. Therefore, the corynebacterium casei can be used for preventing and treating lung injury, especially lung injury caused by radon exposure.

The invention provides a control method and system for interaction between emergency simulation training and a real respirator, and the method comprises the steps: collecting control parameters of the respirator, and carrying out the preprocessing of the control parameters, and obtaining an equipment parameter vector; calculating a physiological response state based on the device parameter vector; the physiological response state comprises alveolar pressure and oxygenation estimation; based on the physiological response state, performing quantitative judgment on the disease stage of the patient to obtain a current disease stage, and executing a corresponding evolution instruction set; a medical specification operation reference table is constructed, a target interval is extracted from the current illness state stage and the evolution instruction set, the matching degree of the target interval and a reference interval is calculated, and the reference interval is extracted from the medical specification operation reference table; determining whether to continue evolution, enter relieving or mark training is completed based on the matching degree; the breathing gas of the patient is simulated and restored through the gas compressor and the gas mixing device and is conveyed to the real breathing machine.

The invention relates to application of hydroxynidone to preparation of a medicine for preventing and / or treating radiation-induced pulmonary fibrosis. Pharmacological experiments prove that the hydroxynidone has a definite resisting effect on radioactive rat lung injury including early inflammatory exudation and pulmonary interstitial fibroblast hyperplasia, and can obviously reduce pulmonary alveolar inflammatory cell exudation and reduce the content of TGF beta 1 in inflammatory exudate; the medium and large doses have the effect of delaying the development of interstitial pneumonia towards pulmonary fibrosis; the lesion degrees of the small, medium and large dosage groups are obviously reduced and are in a dose-effect relationship.

The invention discloses an imitated intercorial nano preparation for treating acute respiratory distress syndrome, and belongs to the technical field of biological medicine. The internalized nano preparation comprises an active component, a liposome phospholipid bilayer and a target head, wherein the active component consists of an ROS (reactive oxygen species) removing drug and an anti-inflammatory drug. According to the invention, efficient and accurate targeting of the nano-preparation is realized by innovatively applying an imitated interment effect, an apoptotic cell marker is modified on the surface of the liposome, and an'eat me 'signal is released to simulate a natural biological process that macrophages clear apoptotic cells to be recognized and swallowed by alveolar macrophages, so that efficient and specific targeting is realized, and the targeting effect of the nano-preparation is improved. Meanwhile, up-regulation of PS receptor expression of macrophages at the inflammation part further enhances the targeting effect, and a new way is provided for efficient delivery of acute respiratory distress syndrome medicine preparations and remodeling of pathological microenvironment.

The invention belongs to the technical field of application of plant exosomes, and discloses a plant-derived hybrid exosome and application of the plant-derived hybrid exosome in pulmonary fibrosis resistance. After screening a proper proportion, the obtained hybrid exosome has an obvious treatment effect on a mouse with pulmonary fibrosis induced by bleomycin, and the treatment effect is specifically shown as follows: (1) the hybrid exosome can obviously relieve lung inflammatory cell infiltration of the model mouse, protect a pulmonary alveolar structure and relieve the degree of pulmonary fibrosis; (2) the hybrid exosome can effectively reduce the expression levels of TNF-alpha, IL-1beta and IL-6, and can effectively slow down the pulmonary fibrosis process; the lung tissue inflammation is inhibited; and (3) the hybridized exosome inhibits the generation of ECM (extracellular matrix) and inhibits epithelial mesenchymal transition, so that the anti-fibrosis effect is achieved. The plant source hybrid exosome prepared by the invention is wide in plant source, simple in exosome preparation process and low in cost, and provides new possibility for treating pulmonary fibrosis.

The utility model relates to a gas collecting device for an expiration test, which effectively solves the problems that the existing expiration collecting device is inconvenient to remove interference gas, and is inconvenient to classify, collect and store gas exhaled by a detector in different time periods, so that the accuracy of an expiration test result is influenced. According to the expiration test gas collection device, cavity gas in a cavity of a detector can enter the gas circulation structure at the first time and is stored in the interference gas collection structure, so that the cavity gas is removed, and alveolar gas exhaled by the detector subsequently flows through the rotating structure and enters one gas storage bag in the gas storage structure; a filtering block in the rotating structure filters out part of non-target gas, so that the accuracy of a detection result is improved; the gas storage structure and the rotating structure can be convenient for a detector to store exhaled gas into different gas storage bags in different time periods, so that exhaled gas samples in different time periods can be stored in batches, and the accuracy of exhaled gas detection results is further improved.

The invention discloses application of peimisine in preparation of an anti-fibrosis medicine, and belongs to the technical field of biological medicines. According to the application, mouse pulmonary interstitial fibrosis is induced through bleomycin, the treatment effect of peimine on pulmonary fibrosis is observed, and the influence of peimine on the pulmonary fibrosis process is explored. Results show that peimisine can reduce mouse lung index increase caused by bleomycin, improve damage of pulmonary alveolar structures of mice with pulmonary fibrosis, reduce aggregation of inflammatory cells, reduce serum fibrosis factors TGF-beta1 and inflammatory factors IL-2 of the mice with pulmonary fibrosis, and reduce the number of macrophages and neutrophils in BALF of the mice with pulmonary fibrosis. The peimisine has an obvious regulating effect on MRC-5 cell abnormal proliferation induced by TGF-beta1, can improve in-vivo pulmonary fibrosis induced by bleomycin by regulating the process of extracellular matrix and intercellular matrix, has an obvious treatment effect on mouse pulmonary fibrosis induced by bleomycin, is beneficial to development and utilization of peimisine, and has a good application prospect. And an effective method is provided for clinical treatment of pulmonary fibrosis.

Provided is a use of a Galectin-1 inhibitor in preparation of a drug for treating pulmonary fibrosis. Taking silicosis model mice as a subject, administration of a Galectin-1 inhibitor OTX008 to silicosis mice can effectively alleviate the progression of pulmonary fibrosis. Studies have shown that the lung function of mice with silicosis is improved significantly; transcription levels of inflammatory factors Il-1β and Il-6 in the lung tissue of silicosis mice are decreased, concentrations of IL-1β and IL-6 in the alveolar lavage fluid are also decreased, and the infiltration of inflammatory cells is decreased. In the lung tissue of silicosis mice, the transcription levels of fibrosis factors Col-I and Fn-1 are decreased, the collagen-specific amino acid hydroxyproline is decreased, the fibrosis lesions are decreased, and the degree of lesions is alleviated. Therefore, the Galectin-1 inhibitor can be used as a new treatment strategy for pulmonary fibrosis.

The invention discloses a construction and evaluation method of an organ chip for evaluating smoke lung injury, which comprises the following steps of: determining the design size and the thickness of the chip, determining to take a corresponding amount of Sylgard 184 base glue according to the design size and the required thickness of the lung organ chip, mixing the base glue and a curing agent according to the weight ratio, and performing extrusion molding to obtain the organ chip for evaluating smoke lung injury. The method comprises the following steps: selecting a PET film with a proper aperture, simulating a gas exchange barrier between pulmonary alveoli and capillaries, cutting according to the size of a cavity constructed by a chip, pretreating the PET film, namely soaking the PET film with absolute ethyl alcohol before use, removing possible impurities and oil stains on the surface of the film, washing with deionized water, and drying to obtain the PET film. The construction method of the smoke lung injury organ chip is simple, stable performance of cells in the chip can be guaranteed in the culture process, and cell culture and gas and nutrient substance exchange simulation are facilitated.

The invention belongs to the field of respiratory system disease treatment, and provides application of a gymnadenia conopsea extract in preparation of a medicine for treating or preventing pulmonary edema. The embodiment of the invention proves that both the gymnadenia conopsea alcohol extract and the gymnadenia conopsea water extract can effectively improve indexes such as pulmonary edema respiratory rate, minute ventilation volume, rising tidal volume, inspiration peak flow, expiration peak flow and the like, and improve arterial blood-gas indexes and inflammatory factor level in alveolar lavage fluid. The invention provides the application of the gymnadenia conopsea alcohol extract and the gymnadenia conopsea water extract in the medicine for treating or preventing lung diseases, especially pulmonary edema for the first time, the traditional medicine gymnadenia conopsea is fully developed and utilized, and a safe and effective means is provided for treating the critical disease pulmonary edema.

The invention discloses a pulmonary alveolar lavage device for children pneumonia patients, and relates to the technical field of medical instruments, the pulmonary alveolar lavage device comprises a lavage device and a suction pipe, the suction pipe is fixedly communicated with the lavage device, one end of the suction pipe far away from the lavage device is provided with a sealing assembly, the sealing assembly comprises a bearing box, and the bearing box is fixedly communicated with one end of the suction pipe far away from the lavage device. A long rod support is fixedly connected to the outer side wall of the bearing box. By means of continuous operation of the progressive assembly, follow-up full-filled collection bottles and pushing of the previous collection bottle, the full-filled collection bottles are arranged on the workbench in a linear array mode, the filling sequence of the collection bottles can be determined, follow-up detection and analysis are helped, and the accuracy and traceability of the detection result are ensured, for example, the detection efficiency is improved. When the lavage fluid is subjected to microbiological culture and analysis, the dynamic change of an illness state can be judged by knowing the perfusion sequence of the sample, and the change condition of pathogens in the lavage fluid at different stages can be observed.

The invention discloses an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury, relates to the technical field of biological medicines, and particularly relates to an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury. The resveratrol is used for preparing the medicine for treating the pulmonary ischemia reperfusion injury, and the resveratrol in the medicine inhibits cell apoptosis by activating an RSPO3 / Wnt / beta-catenin signal channel, so that the pulmonary ischemia reperfusion injury is relieved; the resveratrol in the medicine can relieve the pulmonary ischemia reperfusion injury by inhibiting apoptosis of alveolar macrophages induced by hypoxia / reoxygenation; the conditions for inhibiting apoptosis induced by hypoxia / reoxygenation by adopting resveratrol are as follows: the resveratrol with the concentration of 2.5 mu M is adopted to pretreat macrophages; the resveratrol plays a protection role by activating an RSPO3 / Wnt / beta-catenin signal channel, and a new basis is provided for the medical application; the resveratrol is applied to preparation of the medicine for treating the lung ischemia-reperfusion injury, cell apoptosis is inhibited, and lung tissue injury is relieved.

The application discloses use of LncRNA00_178, miR-466b-3p and Gucy1b1 as acute lung injury markers or drug targets, and belongs to the technical field of biomarkers and drug targets. LncRNA00_178 can be used as a biomarker for screening or diagnosing acute lung injury, a miR-466b-3p down-regulator can be used to prepare a pharmaceutical composition for preventing and treating acute lung injury, and Gucy1b1 can be used as a drug target to prepare a drug for preventing and / or treating acute lung injury. The application has the beneficial effects that the application proposes that LncRNA00_178 and miR-466b-3p, and miR-466b-3p and Gucy1b1 have a target binding relationship. LncRNA00_178 can be used as a biomarker for screening or diagnosing acute lung injury, the silence of miR-466b-3p inhibits LPS-induced apoptosis of alveolar epithelial cells, and Gucy1b1 can be used as a drug target to prepare a drug for preventing and / or treating acute lung injury. The data provide new insights for the treatment mechanism of ALI and the identification of specific targets, and provide a new idea for the research and development of new drugs for acute lung injury, and have a wide application prospect.

The invention discloses a transrespiratory tract noninvasive drug delivery carrier and a preparation method and application thereof.The transrespiratory tract noninvasive drug delivery carrier comprises a lipid bimolecular layer and bioactive ingredients wrapped in the lipid bimolecular layer, and the lipid bimolecular layer comprises a liposome membrane and an enzyme responsive modification part embedded into the liposome membrane; the enzyme responsive modification part is a substrate polypeptide capable of being degraded by RTC-enz and polyethylene glycol connected with the substrate polypeptide. According to the invention, an enzyme-responsive modification part is introduced to the surface of a liposome membrane, so that efficient targeted disintegration of the liposome membrane is realized in pulmonary alveoli in an RTC-enz environment. Bioactive components carried by the liposome are uniformly distributed on the surface of a'gas-blood barrier 'in the pulmonary alveolus after the liposome is disintegrated, so that effective retention and uniform dispersion can be realized, and the condition that the liposome which cannot be disintegrated blocks a'gas-liquid' barrier on the surface of the pulmonary alveolus at the end of the respiratory tract is avoided; and potential toxicity caused by transfection of bioactive components carried by liposome which cannot be disintegrated into alveolar epithelial cells is also avoided.

The invention discloses an application of a compound fresh bamboo juice in a guinea pig asthma model, and relates to the field of medicines, a Hartley albino guinea pig is adopted to construct an OVA induced asthma model, and the model is verified to be successfully constructed through evaluation indexes; evaluating the efficacy of the successfully constructed guinea pig asthma model by using different doses of compound fresh bamboo juice, and evaluating the efficacy of the guinea pig asthma model by scoring guinea pig capsaicin stimulation cough inducing times, alveolar lavage fluid leukocyte number, inflammatory factor content, lung tissue hydroxyproline content and behavioral signs. And evaluating the treatment effect of the compound fresh bamboo juice through Western blot detection, lung histopathology and immunofluorescence staining indexes. In a guinea pig asthma model, high-dose and medium-dose groups of the compound fresh bamboo juice can be used for remarkably reducing the number of cough, reducing the number of white blood cells in alveolar lavage fluid and the level of inflammatory factors and inhibiting pulmonary fibrosis, and a good treatment effect is shown. The results provide powerful support for potential application of the compound fresh bamboo juice in asthma treatment.

The invention discloses a construction method and application of a human lung 3D cell microsphere and a human pulmonary fibrosis 3D organoid. The construction of the human lung 3D cell microspheres comprises the following steps: respectively digesting human primary fibrosis cells and human II-type alveolar epithelial cells which are subjected to adherent culture into single cells; mixing digested human primary fibrotic cells, human II-type alveolar epithelial cells and THP-1 macrophages subjected to suspension culture according to a cell number ratio of 1: 1: 1, so as to obtain a cell precipitate; and preparing the cell precipitate into cell matrigel microspheres by using a T-type microfluidic technology, and culturing to obtain the human lung 3D cell microspheres. And further inducing the human lung 3D cell microspheres by using a human lung organoid culture medium containing 50ng / mL of TGF-beta for 24-48 hours to obtain the human pulmonary fibrosis 3D organoid. According to the invention, 3D cell microspheres with human normal lung cell characteristics and protein expression can be formed within 3 days, and pulmonary fibrosis 3D organs can be obtained after short-time induction.

The utility model discloses a small animal alveolar lavage device which comprises an oxygen tank and a lavage fluid tank on the right side of the oxygen tank, a needle cylinder is arranged on the left side of the oxygen tank, a controller is fixedly connected to the outer wall of the right end of the needle cylinder, and a fluid outlet pipe is fixedly connected to the portion, close to the right side, of the outer wall of the lower end of the needle cylinder so that lavage fluid can be communicated with oxygen to be sprayed out. A liquid return pipe is arranged on the left side of the liquid outlet pipe to recycle used irrigation liquid, a waste liquid tank is arranged on the left side of the needle cylinder to collect waste liquid, a guide pipe c is arranged between the waste liquid tank and the needle cylinder to guide the moving direction of the waste liquid, and a guide pipe a is arranged between the oxygen tank and the needle cylinder to guide circulation of oxygen. A guide pipe b is arranged between the irrigation solution tank and the needle cylinder to guide irrigation solution to circulate, and by installing a temporary storage bubble, a handle, a threaded rod and a movable ring, waste liquid is prevented from dripping on the ground, so that the ground is prevented from being polluted, the time of the irrigation process is shortened, and the irrigation speed is increased.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine nano preparation and application thereof in preparation of a medicine for preventing / treating PM2.5 induced lung injury. The invention provides a traditional Chinese medicine nano preparation. The traditional Chinese medicine nano preparation comprises nobiletin, formononetin and a carrier. According to the traditional Chinese medicine nano preparation, the nobiletin and the formononetin are entrapped in the carrier to form the nano particles with uniform particle size and good dispersity, so that the problems of poor water solubility and low bioavailability of the medicine can be effectively improved, the lung targeted delivery is enhanced, and the residence time of the medicine in the lung is prolonged. According to the traditional Chinese medicine nano preparation, the expression of ZO-1, OCLN, E-cad and other connexins is remarkably improved by inhibiting the EGFR pathway, the alveolar epithelial barrier structure and function are protected, and the inflammatory response and oxidative stress induced by PM2.5 are relieved, so that the lung injury induced by PM2.5 is effectively prevented and treated.

The present invention relates to the use of antisecretory factor (AF) protein, homologues, and / or fragments thereof, having equivalent functional activity, and / or a pharmaceutically active salt thereof, for restoring and / or normalizing epithelial barrier function for treating and / or preventing acute respiratory failure.In particular, antisecretory factor (AF) protein, homologues, and / or fragments thereof, having equivalent functional activity, and / or a pharmaceutically active salt thereof, is (are) herein disclosed to be of use in counteracting and / or normalizing fluid transfer across epithelial cell barriers with a significant impact on a large proportion of patients with traumatic lung injury, such as but not limited to patients suffering from abnormal accumulation of fluid in the lung alveoli and / or bronchioles selected from the list of patients suffering from BPD, ARDS, IRDS, sepsis, SIRS, acute pulmonary edema, pneumonia, interstitial pulmonary edema and cardiovascular lung disorder.

The utility model relates to the technical field of medical instruments, and discloses a specimen bottle for collecting alveolar lavage fluid, which is characterized by comprising a bottle body (1), a first cover (2) and a second cover (6), the first cover (2) and the second cover (6) are arranged at two ends of the bottle body (1), and the first cover (2) and the second cover (6) are detachably connected with the bottle body (1) through threads. An inoculation funnel (3) is arranged at one end, connected with the second cover (6), of the bottle body (1), an inoculation sampling opening (4) is formed in the end point of the inoculation funnel (3), when the covers are tightly covered, the inoculation sampling opening (4) can be extruded to generate a sealing effect, after the first cover (2) is opened, a material needing to be inoculated is put in, and the second cover (6) can be opened during inoculation, so that the second cover (6) can be conveniently opened. And sampling by using the inoculation funnel (3). The use of a traditional inoculating loop is avoided, and the probability of pollution and / or propagation in the operation process is reduced.

The invention discloses an exhaled air nitric oxide (FeNO) detection system based on CO2 calibration, and belongs to the technical field of medical detection equipment. Comprising a gas collection module, a gas calibration module, a detection pool and a pressure control module, the gas collecting module comprises a two-way blowing handle, a one-way valve and a molecular sieve filtering cavity which are arranged in the two-way blowing handle, and a flow sensor arranged outside an expiration channel, and is used for separating and filtering interference gas; the gas calibration module monitors the CO2 concentration in expired gas in real time through a CO2 sensor array, when the CO2 concentration reaches 4%, FeNO detection is triggered, and pulmonary alveolar gas is accurately calibrated; the pressure control module adjusts the flow through linkage of a vacuum pump, a needle valve and a pressure sensor, and maintains the pressure of the detection pool to be stabilized at 0.3 atm. Through CO2 concentration calibration and dynamic pressure control, the problems of identification deviation and insufficient detection precision of alveolar gas in the prior art are solved, the detection error is smaller than or equal to 1 ppb, and the method is suitable for portable medical detection scenes.

The invention belongs to the technical field of biological medicines, and particularly relates to a honeysuckle total extract inhalation solution as well as a preparation method and application thereof. According to the invention, the honeysuckle total extract with poor water solubility, phospholipid and chitosan are innovatively and directionally assembled into the chitosan-phospholipid nanoparticles with uniform structure, and the nanoparticles are prepared by adopting a microfluidic technology. The strategy significantly improves the water solubility and stability of the honeysuckle total extract, and successfully prepares an inhalation solution suitable for pulmonary administration based on the nanoparticle dispersion system. The obtained preparation has the characteristics of high physical stability and good bioavailability potential. The honeysuckle total extract inhalation solution provided by the invention can effectively relieve the pathological process of the pyotoxic pneumonia through multiple mechanisms of remarkably inhibiting lung inflammatory response, relieving pulmonary edema, protecting the structural integrity of pulmonary alveoli and the like. Especially, a high-dose group shows a curative effect superior to that of a positive control drug, and a good dose-effect relationship is combined, so that the preparation has remarkable development potential and clinical transformation prospect in treatment of the septic pneumonia.

A method and a system of deploying an ignition interlock device (IID). The method comprises receiving a time series of breath alcohol content (BrAC) measurements that are unitarily sourced from a pre-identified user, each BrAC measurement of the time series including an alveolar breath component and an interferent breath component; estimating a dissipation rate of alcohol attributable to the pre-identified user in accordance with the time series of BrAC measurements; determining, responsive to estimating the dissipation rate of alcohol, at least a subset of the BrAC measurements as being based on the alveolar breath component but not the interferent breath component; and performing one of triggering and not triggering the IID into a lockout state based on the at least a subset of the BrAC measurements.

The invention relates to the technical field of medical instruments, in particular to a tuberculosis ward atomization respirator with a negative pressure collection function, comprising: a mask assembly, the mask assembly comprises a breathing mask and a sealing strip, and the breathing mask is internally provided with an air pressure sensor for identifying air pressure change; the atomization assembly is connected with the mask assembly and used for intermittently conveying atomized medicine into the breathing mask. During expiration, the airflow adjusting assembly does not hinder the gas flow rate of the gas feeding pipe, the gas flow rate is increased, and a low-pressure area is formed at the position of the pressure-adjustable one-way valve assembly, so that the pressure-adjustable one-way valve assembly does not hinder communication of the exhaust pipe and the negative-pressure pipe; the exhaust gas in the breathing mask is exhausted outwards through the exhaust pipe and the negative pressure pipe, the airflow adjusting assembly reduces the gas flow rate of the gas feeding pipe at the end of expiration, negative pressure collection is not conducted on the gas in the breathing mask at the end of expiration any more, namely positive pressure is provided at the end of expiration, and early closure of pulmonary alveoli is avoided.

The present application relates to the field of biological medicine, in particular to a sensitizing agent for constructing a neutrophilic asthma animal model, a construction method and application. The present application uses Haemophilus influenzae outer membrane vesicles and ovalbumin as a sensitizing agent to construct a neutrophilic asthma animal model, and the test results show that the level of neutrophils in the blood and lung lavage fluid of mice is significantly increased compared with the treatment of ovalbumin as a sensitizing agent alone. The constructed mouse neutrophilic asthma model can be used for the research on the mechanism of clinical neutrophilic asthma and the development of neutrophilic asthma drugs.

The invention relates to the technical field of biological medicines, in particular to application of palmitic acid and a preparation thereof in preparation of medicines for preventing and treating acute exacerbation of chronic obstructive pulmonary diseases. The invention provides application of palmitic acid and a preparation thereof in preparation of a medicine for preventing and treating acute exacerbation of chronic obstructive pulmonary disease. Research finds that supplement of palmitic acid in an acute infection period can improve IFITM3 protein expression of alveolar epithelial cells and further promote downstream secretion of TGF beta by up-regulating the expression level of anti-inflammatory cytokines, so that lung tissue inflammation regression and tissue repair are promoted, and the lung function of patients with chronic obstructive pulmonary diseases is improved.

The invention discloses a construction method of an endothelial cell knockout Cdc42 gene aggravated bleomycin induced pulmonary fibrosis mouse model, which comprises the following steps of: mating a Cdc42 gene conditional knockout mouse with a mouse (Tie2-CreER) of which the endothelial cell specifically expresses tamoxifen induced Cre recombinase to obtain a double-transgenic mouse (Cdc42fl / fl-Tie2-CreER); the Cdc42 gene is specifically knocked out in vascular endothelial cells under the induction of tamoxifen, and then pulmonary fibrosis is induced by subcutaneous injection of bleomycin. The model shows aggravated pulmonary fibrosis phenotypes, including collagen deposition increase, alveolar structure damage and fibrosis-related protein expression up-regulation, and is high in construction success rate and good in repeatability. The invention also provides an application of the model in research of systemic sclerosis related interstitial lung disease pathogenesis and screening of anti-pulmonary fibrosis drugs, and an application of the Cdc42 gene as a drug target, and provides an accurate and reliable tool for pulmonary fibrosis research.

The invention discloses a construction method of an animal model for combined induction and exacerbation of asthma. The method comprises the following steps: injecting ovalbumin or dermatophagoides pteronyssinus extract into an intraperitoneal cavity for sensitization; aerosol inhalation of allergen is carried out for airway re-exposure; in the aggravating stage, pathogenic microorganisms such as pseudomonas aeruginosa, aspergillus fumigatus or respiratory syncytial virus are given and exposed to 500 mu g / m PM2.5 aerosol; lung tissue and bronchoalveolar lavage fluid are then detected. The established model shows that the airway resistance is obviously enhanced and persistent, the mucous thrombus formation rate is greater than 50%, the smooth muscle is obviously thickened, and the model is accompanied by eosinophilic granulocyte and neutrophil infiltration and high expression of various inflammatory factors. The model is good in stability and high in repeatability, can truly simulate clinical asthma acute exacerbation and steroid insensitive characteristics, and provides a platform for asthma mechanism research and new drug screening.